WO2007149932A3 - Procédés et compositions pour cibler l'hepsine - Google Patents

Procédés et compositions pour cibler l'hepsine Download PDF

Info

Publication number
WO2007149932A3
WO2007149932A3 PCT/US2007/071688 US2007071688W WO2007149932A3 WO 2007149932 A3 WO2007149932 A3 WO 2007149932A3 US 2007071688 W US2007071688 W US 2007071688W WO 2007149932 A3 WO2007149932 A3 WO 2007149932A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
hepsin
targeting
targeting hepsin
Prior art date
Application number
PCT/US2007/071688
Other languages
English (en)
Other versions
WO2007149932A2 (fr
Inventor
Daniel K Kirchhofer
Rajesh Vij
Original Assignee
Genentech Inc
Daniel K Kirchhofer
Rajesh Vij
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ573178A priority Critical patent/NZ573178A/en
Priority to KR1020097001309A priority patent/KR101410195B1/ko
Priority to BRPI0712273A priority patent/BRPI0712273A8/pt
Priority to AU2007260950A priority patent/AU2007260950B2/en
Application filed by Genentech Inc, Daniel K Kirchhofer, Rajesh Vij filed Critical Genentech Inc
Priority to US12/306,208 priority patent/US8124352B2/en
Priority to JP2009516706A priority patent/JP2009540835A/ja
Priority to CN200780027496.XA priority patent/CN101490088B/zh
Priority to EP07798834A priority patent/EP2044124A2/fr
Priority to CA002656168A priority patent/CA2656168A1/fr
Priority to MX2008015882A priority patent/MX2008015882A/es
Publication of WO2007149932A2 publication Critical patent/WO2007149932A2/fr
Publication of WO2007149932A3 publication Critical patent/WO2007149932A3/fr
Priority to IL195561A priority patent/IL195561A/en
Priority to NO20090333A priority patent/NO20090333L/no
Priority to US13/355,243 priority patent/US8383123B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pregnancy & Childbirth (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des anticorps monoclonaux anti-HEPSINE, et des procédés pour utiliser ces anticorps.
PCT/US2007/071688 2006-06-22 2007-06-20 Procédés et compositions pour cibler l'hepsine WO2007149932A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP2009516706A JP2009540835A (ja) 2006-06-22 2007-06-20 ヘプシンをターゲティングするための方法と組成物
BRPI0712273A BRPI0712273A8 (pt) 2006-06-22 2007-06-20 anticorpos isolados, polipeptídeos imunoglobulinas, anticorpo hepsina, molécula de ácido nucléico, célula hospedeira, linhagem celular, métodos para produzir o anticorpo, para diagnosticar a presença de hepsina, tratar uma doença, para monitorar a doença residual, para detectar o estado da doença, para diagnosticar uma disfunção, composição, arranjo ou chip de proteína e kit
AU2007260950A AU2007260950B2 (en) 2006-06-22 2007-06-20 Methods and compositions for targeting HEPSIN
EP07798834A EP2044124A2 (fr) 2006-06-22 2007-06-20 Procédés et compositions pour cibler l'hepsine
US12/306,208 US8124352B2 (en) 2006-06-22 2007-06-20 Methods and compositions for targeting HEPSIN
KR1020097001309A KR101410195B1 (ko) 2006-06-22 2007-06-20 헵신을 표적화하기 위한 방법 및 조성물
CN200780027496.XA CN101490088B (zh) 2006-06-22 2007-06-20 用于靶向hepsin的方法和组合物
NZ573178A NZ573178A (en) 2006-06-22 2007-06-20 Methods and compositions for targeting hepsin
CA002656168A CA2656168A1 (fr) 2006-06-22 2007-06-20 Procedes et compositions pour cibler l'hepsine
MX2008015882A MX2008015882A (es) 2006-06-22 2007-06-20 Metodos y composiciones para hacer blanco en hepsina.
IL195561A IL195561A (en) 2006-06-22 2008-11-27 Methods and preparations for finding hepsin
NO20090333A NO20090333L (no) 2006-06-22 2009-01-21 Fremgangsmater og preparater rettet mot hepsin
US13/355,243 US8383123B2 (en) 2006-06-22 2012-01-20 Method of treatment targeting HEPSIN

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80558906P 2006-06-22 2006-06-22
US60/805,589 2006-06-22

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/306,208 A-371-Of-International US8124352B2 (en) 2006-06-22 2007-06-20 Methods and compositions for targeting HEPSIN
US13/355,243 Division US8383123B2 (en) 2006-06-22 2012-01-20 Method of treatment targeting HEPSIN

Publications (2)

Publication Number Publication Date
WO2007149932A2 WO2007149932A2 (fr) 2007-12-27
WO2007149932A3 true WO2007149932A3 (fr) 2008-05-02

Family

ID=38754528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/071688 WO2007149932A2 (fr) 2006-06-22 2007-06-20 Procédés et compositions pour cibler l'hepsine

Country Status (16)

Country Link
US (2) US8124352B2 (fr)
EP (1) EP2044124A2 (fr)
JP (1) JP2009540835A (fr)
KR (1) KR101410195B1 (fr)
CN (1) CN101490088B (fr)
AU (1) AU2007260950B2 (fr)
BR (1) BRPI0712273A8 (fr)
CA (1) CA2656168A1 (fr)
IL (1) IL195561A (fr)
MX (1) MX2008015882A (fr)
MY (1) MY150643A (fr)
NO (1) NO20090333L (fr)
NZ (1) NZ573178A (fr)
RU (1) RU2009101813A (fr)
WO (1) WO2007149932A2 (fr)
ZA (1) ZA200810225B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275547B1 (fr) 2004-12-13 2014-03-05 Alethia Biotherapeutics Inc. Polynucléotides et séquences de polypeptide impliquées dans le procédé de remodelage des os
AU2007260950B2 (en) 2006-06-22 2011-09-15 Genentech, Inc. Methods and compositions for targeting HEPSIN
US8435511B2 (en) 2009-10-22 2013-05-07 Genentech, Inc. Anti-hepsin antibodies and methods using same
US8697386B2 (en) 2009-10-22 2014-04-15 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011109308A1 (fr) 2010-03-02 2011-09-09 Seattle Genetics, Inc. Procédés pour cribler des anticorps
WO2011161189A1 (fr) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anticorps anti-hepsine et leurs procédés d'utilisation
JP6263467B2 (ja) * 2011-05-27 2018-01-17 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｂｃｍａ（ｃｄ２６９／ｔｎｆｒｓｆ１７）結合タンパク質
UA112434C2 (uk) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
WO2017162659A1 (fr) 2016-03-24 2017-09-28 Bayer Pharma Aktiengesellschaft Hepsine intracellulaire en tant que cible thérapeutique pour le traitement du cancer à l'aide d'une amplification de centrosomes

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016484A2 (fr) * 2001-08-17 2003-02-27 Affymetrix, Inc. Genes du cancer de la prostate de score de gleason 4/5
WO2004033630A2 (fr) * 2002-10-04 2004-04-22 Schering Aktiengesellschaft Molecules d'hepsine modifiees comprenant une sequence d'activation de substitution et utilisations de celles-ci

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6268165B1 (en) 1997-03-19 2001-07-31 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
US7282198B2 (en) 1997-03-19 2007-10-16 The University Of Arkansas For Medical Sciences Immunotherapeutic methods targeted towards stratum corneum chymotryptic enzyme
US5981830A (en) 1997-05-30 1999-11-09 Schering Aktiengesellschaft Knockout mice and their progeny with a disrupted hepsin gene
WO2001057194A2 (fr) 2000-02-03 2001-08-09 Corvas International, Inc. Molecules d'acides nucleiques codant pour des proteases a serine transmembranaires, proteines codees et procedes associes
US6423543B1 (en) 2000-12-20 2002-07-23 Isis Pharmaceuticals, Inc. Antisense modulation of hepsin expression
EP1425413A2 (fr) 2001-01-23 2004-06-09 Irm, Llc Genes surexprimes dans des maladies de la prostate servant de cibles diagnostiques et therapeutiques
CA2438433A1 (fr) 2001-02-14 2002-08-22 Tularik Inc. Gene amplifie de l'hepsine associee au cancer
US6482630B2 (en) 2001-03-29 2002-11-19 Applera Corporation Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
WO2003064620A2 (fr) 2002-01-31 2003-08-07 Irm, Llc Substrats de l'hepsine et promedicaments
US20040001801A1 (en) 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
JP3775346B2 (ja) * 2002-05-29 2006-05-17 株式会社日立製作所 テレビ電話システムおよびその端末装置
AU2003260316A1 (en) 2002-07-23 2004-02-09 Bayer Healthcare Ag Regulation of human hepsin
US6977170B2 (en) 2002-09-06 2005-12-20 Applera Corporation Isolated human hepsin/46 proteins, nucleic acid molecules encoding human hepsin/46 proteins, and uses thereof
CN101023182B (zh) 2004-07-26 2013-04-17 健泰科生物技术公司 调节肝细胞生长因子活化的方法和组合物
WO2007149935A2 (fr) 2006-06-22 2007-12-27 Genentech, Inc. Procédés et compositions pour moduler l'activation de l'hepsine de l'activateur du plasminogène de type urokinase
AU2007260950B2 (en) 2006-06-22 2011-09-15 Genentech, Inc. Methods and compositions for targeting HEPSIN
US8435511B2 (en) * 2009-10-22 2013-05-07 Genentech, Inc. Anti-hepsin antibodies and methods using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016484A2 (fr) * 2001-08-17 2003-02-27 Affymetrix, Inc. Genes du cancer de la prostate de score de gleason 4/5
WO2004033630A2 (fr) * 2002-10-04 2004-04-22 Schering Aktiengesellschaft Molecules d'hepsine modifiees comprenant une sequence d'activation de substitution et utilisations de celles-ci

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HAAB BRIAN B: "Antibody Arrays in cancer research", MOLECULAR & CELLULAR PROTEOMICS, vol. 4, no. 4, April 2005 (2005-04-01), pages 377 - 383, XP002461478, ISSN: 1535-9476 *
LANDERS K A ET AL: "Use of Multiple Biomarkers for a Molecular Diagnosis of Prostate Cancer", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 114, 10 May 2005 (2005-05-10), pages 950 - 956, XP003010224, ISSN: 0020-7136 *
XUAN J-A ET AL: "Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture", CANCER RESEARCH 01 APR 2006 UNITED STATES, vol. 66, no. 7, 1 April 2006 (2006-04-01), pages 3611 - 3619, XP002461477, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
KR101410195B1 (ko) 2014-06-19
NZ573178A (en) 2012-02-24
CA2656168A1 (fr) 2007-12-27
MX2008015882A (es) 2009-01-12
WO2007149932A2 (fr) 2007-12-27
IL195561A0 (en) 2011-08-01
ZA200810225B (en) 2010-03-31
IL195561A (en) 2013-04-30
US20120141374A1 (en) 2012-06-07
US8383123B2 (en) 2013-02-26
CN101490088A (zh) 2009-07-22
RU2009101813A (ru) 2010-07-27
JP2009540835A (ja) 2009-11-26
CN101490088B (zh) 2015-04-08
AU2007260950A1 (en) 2007-12-27
BRPI0712273A8 (pt) 2019-01-22
KR20090029276A (ko) 2009-03-20
AU2007260950B2 (en) 2011-09-15
AU2007260950A8 (en) 2009-01-22
NO20090333L (no) 2009-03-23
US8124352B2 (en) 2012-02-28
EP2044124A2 (fr) 2009-04-08
MY150643A (en) 2014-02-14
BRPI0712273A2 (pt) 2012-03-06
US20100021474A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
WO2007120334A8 (fr) Méthodes et compositions de ciblage de la polyubiquitine
WO2009126350A3 (fr) Procédés et compositions pour cibler la polyubiquitine
WO2008052187A3 (fr) Anticorps et immunoconjugués, et leurs utilisations
WO2007130697A3 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
WO2007133290A3 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2007106744A8 (fr) Anticorps anti-5t4 et leurs utilisations
WO2006083936A3 (fr) Anticorps anti-ephb2 et methodes d'utilisation associees
WO2007149932A3 (fr) Procédés et compositions pour cibler l'hepsine
WO2008060705A8 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
IL204542A (en) Unique monoclonal antibodies for protofibrillary form of cellulose-amyloid protein, methods and uses thereof
WO2008082987A3 (fr) Protections et méthodes pour appareils de mesure de substances à analyser
WO2008002893A8 (fr) Anticorps anti-amyloïdes, compositions, procédés et utilisations
WO2007008943A3 (fr) Proteines optimisees qui ciblent la molecule ep-cam
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
WO2007127506A8 (fr) Anticorps anti-ephrinb2 et procédés les utilisant
WO2006118862A3 (fr) Methodes de protection du verre
WO2008066630A3 (fr) Procédés de reprogrammation de cellules somatiques adultes, et leurs utilisations
IL193392A0 (en) Influenza antibodies, compositions, and related methods
WO2007112279A3 (fr) Résonateurs
WO2008027600A3 (fr) Compositions d'imatinib
WO2010014258A3 (fr) Conjugués possédant une liaison libérable
WO2007106915A8 (fr) Anticorps à efgl 7 et leurs procédés d'utilisation
WO2007056083A3 (fr) Inhibiteurs de fusions polypeptidiques biosynthetiques
WO2011050188A8 (fr) Anticorps anti-hepsine et procédés d'utilisation de ceux-ci
WO2007117763A3 (fr) Procédés et compositions destinés à cibler relt

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780027496.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07798834

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 9840/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 573178

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007260950

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 12008502661

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/015882

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2656168

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009516706

Country of ref document: JP

Ref document number: 08135859

Country of ref document: CO

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007260950

Country of ref document: AU

Date of ref document: 20070620

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007798834

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020097001309

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009101813

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12306208

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0712273

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081218